RecruitingPHASE1, PHASE2NCT04683250
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Intervention
- TAS0953/HM06(drug)
- Enrollment
- 244 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2031
Study locations (21)
- Chao Family Comprehensive Cancer Center, Orange, California, United States
- Stanford Cancer Center, Stanford, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- START Midwest - Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, United States
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
- Tohoku University Hospital, Sendai, Miyagi, Japan
- Okayama University Hospital, Okayama, Okayama-ken, Japan
- Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
- Osaka International Cancer Institute, Osaka, Osaka, Japan
- Shizuoka Cancer Center, Shizuoka, Shizuoka, Japan
- +6 more locations on ClinicalTrials.gov
Collaborators
Linical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04683250 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital